TRIM25 Knockout A-549 Cell Line
Cat.No.:
EDC09755
Species:
Human
Cell Name:
A-549
Gene:
TRIM25
Gene ID:
7706
Size:
1×10⁶cells
TRIM25 Knockout Cell Line (A549) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC09755 |
|---|---|
| Product Name | TRIM25 Knockout A549 Cell Line |
| Cell Line | A-549 |
| Cellosaurus ID | CVCL_0023 |
| Cell Line Synonyms | A 549, A549, NCI-A549, A549/ATCC, A549 ATCC, A549ATCC, hA549 |
| Gene | TRIM25 |
| NCBI Gene ID | |
| Gene Synonyms | EFP|RNF147|Z147|ZNF147 |
| Summary |
The protein encoded by this gene is a member of the tripartite motif (TRIM) family. The TRIM motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. The protein is an RNA binding protein, functions as a ubiquitin E3 ligase and is involved in multiple cellular processes, including regulation of antiviral innate immunity. [provided by RefSeq, Sep 2021]
|
| Associated Diseases | Non-Small Cell Lung Carcinoma |
| Morphology | Adherent |
| Passage Ratio | 1/5-1/4 ,2days |
| Complete Culture Medium | F-12K + 10% FBS |
| Freezing Medium | 95% Complete culture medium + 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: A-549 | STR Info (Cell bank) Cell Line: A-549 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | Y | X | Y |
| CSF1PO | 10 | 12 | 10 | 12 |
| D2S1338 | 24 | 24 | ||
| D3S1358 | 16 | 16 | ||
| D5S818 | 11 | 11 | ||
| D7S820 | 8 | 11 | 8 | 11 |
| D8S1179 | 13 | 14 | 13 | 14 |
| D13S317 | 11 | 11 | ||
| D16S539 | 11 | 12 | 11 | 12 |
| D18S51 | 14 | 17 | 14 | 17 |
| D19S433 | 13 | 13 | ||
| D21S11 | 29 | 29 | ||
| FGA | 23 | 23 | ||
| Penta D | 9 | 9 | ||
| Penta E | 7 | 11 | 7 | 11 |
| TH01 | 8 | 9.3 | 8 | 9.3 |
| TPOX | 8 | 11 | 8 | 11 |
| vWA | 14 | 14 | ||
| D6S1043 | 11 | 13 | ||
| D12S391 | 18 | 18 | ||
| D2S441 | 10 | 13 | 10 | 13 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying TRIM25 function, TRIM25 Knockout A-549 Cell Line or TRIM25 overexpression A-549 Cell Line?
The choice depends on whether you are studying TRIM25's role in RIG-I-mediated antiviral signaling or its broader functions in ubiquitin ligase biology. The Knockout line is the standard tool for asking whether TRIM25 is required for K63-linked ubiquitination of RIG-I and downstream type I IFN induction — particularly relevant in A-549, which is widely used in respiratory viral infection studies. Overexpression is useful for testing whether elevated TRIM25 enhances antiviral signaling or for studying TRIM25's RNA-binding functions independent of its E3 ligase activity.
For antiviral immunity research, the EDITGENE Knockout line in A-549 is highly informative — A-549 supports replication of many respiratory viruses (influenza, SARS-CoV-2, RSV), enabling direct testing of TRIM25's antiviral functions in a disease-relevant context. Rescue with wild-type, RING-dead, or RNA-binding-deficient TRIM25 is the standard approach for dissecting its dual ligase and RNA-binding activities.
What are the application scenarios for this model?
Primary applications:
• RIG-I ubiquitination assays: Western blot analysis of K63-linked ubiquitination on RIG-I following viral RNA stimulation or poly(I:C) treatment.
• Type I IFN induction: IFN-β reporter assays and ISG expression analysis following viral infection (influenza, SARS-CoV-2, Sendai virus) or viral mimics.
• Antiviral activity: viral replication assays in A-549 to assess functional consequences of disrupted TRIM25-mediated RIG-I activation.
• Substrate identification: TRIM25 ubiquitination targets beyond RIG-I have been reported; ubiquitin proteomics in the knockout can expand the substrate catalog.
EDITGENE recommends this model for researchers investigating innate antiviral immunity, respiratory virus infection biology, and RIG-I-MAVS pathway regulation.
Is this TRIM25 Knockout A-549 Cell Line compatible with overexpression rescue experiments?
Yes. TRIM25 rescue experiments require attention to its dual E3 ligase and RNA-binding activities:
• Construct design: use a codon-modified TRIM25 sequence with a small C-terminal tag (FLAG, HA). TRIM25 contains an N-terminal RING domain that should be preserved with minimal N-terminal modification.
• RING-dead rescue: the C20A/H22A double mutation in the RING domain abolishes E3 ligase activity and is the standard control for separating ligase from RNA-binding functions.
• RNA-binding-deficient rescue: specific PRY/SPRY domain mutations affect TRIM25's RNA binding without disrupting E3 activity — these constructs are critical for dissecting RNA-binding-specific functions.
• Functional readout: rescue should restore RIG-I ubiquitination and IFN induction following viral RNA stimulation in A-549.
A-549 transduces efficiently with lentivirus and supports stable rescue line generation; the NSCLC background is particularly suited to studying TRIM25 in respiratory virus infection contexts.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
download